Research Information System
Other, pp.1-39, 2021
The HIV-1 and its variants have claimed more than 32.7
million lives since its emergence in 1981, while many highly/ active
antiretroviral therapies are available but most of these therapeutics have
long-term side effects. In this study, genomic analysis was performed on 98
HIV-1 genomes to determine the most coherent target, which could be utilized
for termination of the viral replication and the reverse transcriptase enzyme.
Following the identification of the target protein, the RNase H activity of the
reverse transcriptase was selected as the potential target based on its low
mutation rate and high conservation determined using MAUVE analysis. Afterwards,
a library of around 94.000 small molecule inhibitors was investigated and
virtual screening was performed against the RNase domain of the reverse
transcriptase to identify potential hits. Four compounds with the best scores
were considered and their interaction within the active site was analysed.
Subsequently, all-atom molecular dynamics simulations and MM-PBSA was performed
to validate the stability and binding free energy of the hits within the RNase
H active site. In computational analyses, ADMET assays were performed on the
hit compounds to analyse their drug candidacy based on their physicochemical and pharmacological
properties. Phomoarcherin B, a pentacyclic aromatic sesquiterpene naturally
found in the endophytic fungus Phomopsis archeri, known for its
anticancer properties scored the best in all the experiments and was nominated
as a potential inhibitor of the HIV-1 reverse transcriptase RNase H
activity.